Notify me when Tamarack Advisers, LP files a new 13F portfolio report.
⭐ Subscribe ⭐| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2023 | 1 | $2,120,279 | $0 | -$45,396,269 | -$45,396,269 | STRM | 13F-HR | 08 Feb 2024, 17:42 |
| Q3 2023 | 14 | $50,166,897 | +$2,658,400 | -$70,395,221 | -$67,736,821 | VTRS, BDX, MDRX, MCK, STRM | 13F-HR | 15 Nov 2023, 21:55 |
| Q2 2023 | 30 | $131,574,600 | +$30,517,591 | -$35,455,389 | -$4,937,798 | VTRS, MDRX, PHR, COLL, THC | 13F-HR | 09 Aug 2023, 18:28 |
| Q1 2023 | 34 | $131,112,917 | +$31,839,020 | -$37,526,096 | -$5,687,076 | VTRS, MDRX, PHR, STRM, COLL | 13F-HR | 10 May 2023, 18:06 |
| Q4 2022 | 32 | $138,284,209 | +$32,176,739 | -$65,660,515 | -$33,483,776 | MDRX, VTRS, PHR, CERS, COLL | 13F-HR | 10 Feb 2023, 19:09 |
| Q3 2022 | 42 | $169,407,000 | +$46,952,808 | -$47,249,235 | -$296,427 | LNTH, MDRX, PCRX, PRGO, THC | 13F-HR | 14 Nov 2022, 19:12 |
| Q2 2022 | 39 | $172,242,000 | +$62,381,380 | -$66,804,887 | -$4,423,507 | CI, LNTH, CERS, PCRX, THC | 13F-HR | 15 Aug 2022, 18:39 |
| Q1 2022 | 42 | $209,107,000 | +$70,501,169 | -$107,518,027 | -$37,016,858 | CI, PCRX, LNTH, MRK, BVS | 13F-HR | 11 May 2022, 15:28 |
| Q4 2021 | 44 | $242,128,000 | +$89,429,961 | -$148,085,036 | -$58,655,075 | THC, PCRX, MDT, BVS, SIBN | 13F-HR | 11 Feb 2022, 19:04 |
| Q3 2021 | 36 | $312,410,000 | +$58,428,686 | -$83,433,793 | -$25,005,107 | HSIC, RIGL, MDT, PCRX, PDCO | 13F-HR | 10 Nov 2021, 18:30 |
| Q2 2021 | 40 | $348,817,000 | +$68,220,343 | -$235,432,416 | -$167,212,073 | MDT, RIGL, HSIC, PCRX, TPB | 13F-HR | 12 Aug 2021, 20:08 |
| Q1 2021 | 54 | $481,778,000 | +$128,174,034 | -$161,496,576 | -$33,322,542 | PCRX, MDT, RIGL, PDCO, TPB | 13F-HR | 11 May 2021, 20:31 |
| Q4 2020 | 38 | $470,480,000 | +$132,237,860 | -$42,029,145 | +$90,208,715 | PCRX, MDT, UTHR, RIGL, NUAN | 13F-HR | 09 Feb 2021, 17:32 |
| Q3 2020 | 29 | $318,836,000 | +$56,856,282 | -$96,664,558 | -$39,808,276 | PCRX, MDT, HOLX, PRGO, RIGL | 13F-HR | 10 Nov 2020, 20:19 |
| Q2 2020 | 29 | $348,173,000 | +$106,401,014 | -$86,311,204 | +$20,089,810 | PCRX, DGX, PRGO, UTHR, HOLX | 13F-HR | 10 Aug 2020, 18:07 |
| Q1 2020 | 30 | $259,773,000 | +$78,648,569 | -$179,061,500 | -$100,412,931 | DGX, MDT, ATRC, MDRX, PRGO | 13F-HR | 14 May 2020, 13:48 |
| Q4 2019 | 25 | $436,724,000 | +$87,519,830 | -$65,406,544 | +$22,113,286 | MDT, BIO, MDRX, ATRC, PCRX | 13F-HR | 10 Feb 2020, 20:48 |
| Q3 2019 | 25 | $381,728,000 | +$89,826,773 | -$31,719,526 | +$58,107,247 | MDRX, MDT, BIO, PCRX, PTLA | 13F-HR | 05 Nov 2019, 15:42 |
| Q2 2019 | 19 | $328,608,000 | +$110,630,168 | -$38,993,707 | +$71,636,461 | MDRX, MDT, BIO, PCRX, SRCL | 13F-HR | 12 Aug 2019, 16:58 |
| Q1 2019 | 20 | $251,430,000 | +$65,965,775 | -$88,749,376 | -$22,783,601 | MDRX, MDT, SRCL, PTLA, LNTH | 13F-HR | 13 May 2019, 15:29 |
| Q4 2018 | 20 | $245,057,000 | +$44,078,034 | -$80,716,083 | -$36,638,049 | MDRX, MDT, NUVA, NOVOCURE LTD, ATRC | 13F-HR | 11 Feb 2019, 17:25 |
| Q3 2018 | 24 | $348,092,000 | +$61,819,601 | -$54,721,569 | +$7,098,032 | NUVA, NOVOCURE LTD, LH, MDRX, MDT | 13F-HR | 13 Nov 2018, 13:26 |
| Q2 2018 | 25 | $296,911,000 | +$151,595,444 | -$67,449,815 | +$84,145,629 | NOVOCURE LTD, MDT, NUVA, MDRX, LH | 13F-HR | 14 Aug 2018, 12:53 |
| Q1 2018 | 27 | $210,233,000 | +$104,648,120 | -$70,928,444 | +$33,719,676 | NVCR, NUVA, MDRX, MDT, CORI | 13F-HR | 07 May 2018, 20:11 |
| Q4 2017 | 25 | $181,481,000 | +$52,263,949 | -$51,140,454 | +$1,123,495 | NOVOCURE LTD, MDRX, PCRX, LH, NUVA | 13F-HR | 13 Feb 2018, 18:52 |
| Q3 2017 | 23 | $161,479,000 | +$45,666,321 | -$58,926,725 | -$13,260,404 | MDRX, NOVOCURE LTD, NKTR, MDT, CORI | 13F-HR | 13 Nov 2017, 13:33 |
| Q2 2017 | 26 | $169,869,000 | +$30,292,740 | -$40,324,978 | -$10,032,238 | MDRX, NOVOCURE LTD, NKTR, LH, PCRX | 13F-HR | 07 Aug 2017, 18:30 |
| Q1 2017 | 31 | $159,966,000 | +$56,840,769 | -$54,281,663 | +$2,559,106 | MDRX, PCRX, NKTR, GILD, SPNC | 13F-HR | 12 May 2017, 15:55 |
| Q4 2016 | 27 | $140,573,000 | +$42,491,813 | -$206,540,761 | -$164,048,948 | ARIA, NXTM, HOLX, BIO, PCRX | Restatement | 16 Feb 2017, 15:04 |
| Q3 2016 | 31 | $314,204,000 | $0 | $0 | $0 | ELGX, NXTM, PDCO, ARIA, BIO | New Holdings | 09 Nov 2016, 18:44 |
| Q3 2016 | 31 | $314,204,000 | +$87,994,742 | -$86,281,149 | +$1,713,593 | ELGX, NXTM, PDCO, ARIA, BIO | 13F-HR | 08 Nov 2016, 19:01 |
| Q2 2016 | 28 | $257,731,000 | +$64,790,000 | -$112,637,034 | -$47,847,034 | ELGX, NXTM, IMPR, ARIA, DGX | 13F-HR | 12 Aug 2016, 17:49 |
| Q1 2016 | 19 | $285,163,000 | +$34,841,093 | -$224,673,951 | -$189,832,858 | ELGX, DGX, PDCO, NXTM, MDRX | 13F-HR | 13 May 2016, 20:04 |
| Q4 2015 | 26 | $525,323,000 | $0 | $0 | $0 | PDCO, DGX, ELGX, NXTM, MDT | 13F-HR | 08 Feb 2016, 15:20 |